ClinicalTrials.gg
Not yet recruitingNCT05651880JAKUVEITEUpdated Jun 8, 2026

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

A Phase 3 interventional study of Baricitinib 4 MG in Active Non-anterior Non-infectious Uveitis, sponsored by University Hospital, Rouen. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by University Hospital, Rouen · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Uveitis with a site in France — 5 open to participants now, 7 under way, 2 of them phase 3. Uveitis · France.

Planned enrollment
21st of 26
33 · median 84
Started
2026
with 2 others
Phase 3
14 of 38
1 open now
Registered
35th of 38
by date

Among the 38 studies in Uveitis with a site in France, this one is the 21st largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2026, is one of 14 in phase 3, and was the 35th registered.

Uveitis

300 studies on the registry are indexed under Uveitis; 33 are open to participants now.

Browse Uveitis studies →

Open to participants now

5 of the 38 studies in Uveitis with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 23 Uveitis studies recruiting now, 14 (61%) set no upper age limit and 9 (39%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Uveitis with a site in France, or all of them as a file.
02

Study summary

The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6 months of treatment

03

Conditions studied

  • Active Non-anterior Non-infectious Uveitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with diagnosis of non-anterior non-infectious uveitis, to at least one line of biotherapy (anti-TNF alpha, tocilizumab)
  • Need to stop biotherapy (anti-TNF alpha or tocilizumab) and conventional drugs (mycofenolate mofetil, methotrexate, azathioprine, cyclosporine, interferon alpha 2a) for at least 10 days prior to the inclusion date

Exclusion criteria

Exclusion Criteria:

  • 1. Isolated anterior uveitis. 2. Infectious uveitis. 3. Severe uveitis threatening the visual prognosis and requiring emergency treatment with intravenous .

    4. Initial visual acuity > 1.3 LogMAR in at least one eye. 5. Corneal or lens opacity that prevents fundus visualization or may require cataract surgery during the study.

    6. to baricitinib (OLUMIANT 2 and 4 mg film-coated tablets) : to the active substance or to any of the .

    7. Contraindication to mydriasis. 8. glaucoma in either eye. 9. Monophthalmic patient. 10. Previous treatment with JAK inhibitors. 11. Intraocular corticosteroid injection (subconjunctival or laterobulbar) within 1 month prior to inclusion or intravitreal corticosteroid implant within 3 months prior to inclusion.

    12. Need for treatment with a biotherapy (anti-IL6, anti-IL6 receptor, anti-IL1, anti-IL12/IL23 anti-IL17, anti-BAFF) for extra-ocular involvement, during the entire study period.

    13. Treatment with OAT3 inhibitors with high inhibitory potential such as probenecid, leflunomide, teriflunomide 14. 14. Vaccination with a live or within 15 days prior to inclusion 15. History of cancer within the previous 5 years, except non- squamous cell and basal cell carcinoma of the skin.

    16. Personal history of venous thromboembolic disease.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Patient treated with baricitinib

    Patient treated with baricitinib at a dose of 4 mg per day, taken orally in the morning, with one tablet per day for 6 months.

    Drug: Baricitinib 4 MG

Interventions

  • DrugBaricitinibStudies of BaricitinibBaricitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    4 mg per day for 6 months (For patients with creatinine clearance between 30 and 60 mL/min at baseline or during the study, the dosage of baricitinib will be 2 mg daily)

06

What researchers measure

Primary outcomes

  1. Number of patients with complete remission

    Time frame: 6 months

Secondary outcomes

  1. Number of patients with complete remission

    Time frame: 1 month

  2. Number of patients with complete remission

    Time frame: 3 months

  3. Number of serious events

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2029, 41 months later.

Of 15 phase 3 interventional studies under Uveitis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's planned 41 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Dec 15, 2022
StartEst.
Jul 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05651880
Responsible party
Sponsor
First posted
Dec 15, 2022
Start date
Jul 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jun 8, 2026

Study contacts

Mathilde LECLERCQ, MD
Contact
mathilde.leclercq@chu-rouen.fr
+3323288 ext. 9120
Armelle GUIDOTTI
Contact
armelle.guidotti@chu-rouen.fr
+3323288 ext. 8265
Mathilde LECLERCQ, MD
principal investigator · University Hospital, Rouen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion